Therapeutics Refresher Day
Date: 28/05/2023 (AEST)
Venue: Australian College of Optometry, 374 Cardigan Street, CARLTON, VIC, 3053
Provider: Australian College of Optometry
Contact: Shazia Tahseen, [E] cpd@aco.org.au, [P] 03 9349 7546
Learning Objectives
- Understand the appropriate context and use of oral medications by optometrists
- Understand the appropriate prescribing considerations of these medications
- Understand the appropriate management and safety profile of these medications
- Understand the definition of pre-myopia and risk factors for development of myopia
- Discuss the feasibility of initiation of treatment of pre-myopia with atropine according to risk factors, such as age, ethnicity, parental refractive status, near work/outside exposure time etc
- Compare and contrast the use of atropine therapy vs other therapies in pre-myopia
- Discuss management dilemmas regarding monitoring vs intervention in the management of older myopes who are progressing, for example such as those in their late teens and early 20s
- Appraise the utility of retinal imaging in the differential diagnosis of optic neuropathies and optic neuritis
- Recognise the potential impact of migraine on patient assessment using retinal imaging and development of a management plan
- Critique the latest evidence from systematic reviews about retinal imaging in neurological disorders that may present to optometric practice
- Understand the most frequent causes of and risk factors for cystoid macula oedema
- Discuss the advantages and disadvantages of the different treatment strategies for macula oedema re safety, speed of resolution, accessibility, dependent on cause and need for long term treatment
- Discuss any preventative action that can be taken to reduce the risk of CMO
- Learn about the new treatments becoming available for neovascular and atrophic AMD
- Learn about the importance of multi-modal imaging including OCT and OCT-angiography in the diagnosis and management of AMD, especially with new treatment options on the horizon
- Learn about the current clinical trials on offer for AMD patients and how your patients can be involved
Max CPD hours awarded: 7.25
Session Information
| Name |
|---|
| In practice oral therapeutics - actual case based presentations |
| Clinical? |
| Yes |
| Interactive? |
| Yes |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 1.5 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 1.75 |
| Name |
|---|
| The management of pre-myopia |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 1 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 1.25 |
| Name |
|---|
| Retinal imaging in neuro-optometry: the latest evidence from systematic reviews |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 1 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 1.25 |
| Name |
|---|
| Diagnosis and Management of Cystoid Macula Oedema |
| Clinical? |
| Yes |
| Interactive? |
| Yes |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 1.5 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 1.75 |
| Name |
|---|
| What's new in AMD - biomarkers, novel treatments and clinical trials |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 1 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 1.25 |